Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2010

View Archived Issues

BNC-210 is well tolerated in healthy volunteers

AZ-004 is efficacious in preclinical model of inflammatory pain

Rivaroxaban is as effective as standard therapy in treating deep vein thrombosis

Oral JNJ-41876666 is active against cold allodynia in models of neuropathic pain

New glucagon receptor antagonists claimed by Merck & Co.

Abbott presents new inhibitors of GlyT-1

Shionogi recaps Q1 highlights of fiscal year 2010

New alpha2C-adrenoceptor agonists display antinociceptive effects and cardiovascular safety in vivo

Patient enrollment complete in Antisoma's phase III trial of AS-1413

BMS acquires ZymoGenetics and PEG-interleukin-29 for HCV infection

Transgene and Jennerex enter into exclusive partnership for JX-594

Sylentis to begin new phase I/II trial of SYL-040012 for elevated IOP and glaucoma

NeuroSearch discloses new voltage-gated potassium channel activators

GSK presents new dual histamine H1/H3 receptor antagonists

Merck & Co. discontinues development of MK-6913 for hot flashes

Taisho Pharmaceutical claims new selective SGLT1 inhibitors

N30 Pharma begins dosing in first-in-human phase I trial of N-6022

FDA advisory committee recommends approval of ceftaroline fosamil for CABP and cSSSI

Cempra begins studies of oral and intravenous solithromycin

Phase III trial begins of oral methylnaltrexone in opioid-induced constipation

FDA approves expanded indications for Saphris

Condition for approval removed for Avastin in Japan

Mylan acquires Bioniche Pharma ahead of schedule

Emergent BioSolutions begins phase I trial of inhalational anthrax treatment

FDA approves Abbott RealTime HBV assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...